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   A B S T R A C T  
  Based on DNA analysis of a historical case, the 
authors describe how a female athlete can be 
unknowingly confronted with the consequences 
of a disorder of sex development resulting in 
hyperandrogenism emerging early in her sports 
career. In such a situation, it is harmful and con-
fusing to question sex and gender. Exposure to 
either a low or high level of endogenous testos-
t e r o n e  f r o m  p u b e r t y  i s  a  d e c i s i v e  f a c t o r  w i t h  
respect to sexual dimorphism of physical perfor-
mance. Yet, measurement of testosterone is not 
the means by which questions of an athlete’s 
eligibility to compete with either women or men 
are resolved. The authors discuss that it might 
be justiﬁ  able to use the circulating testosterone 
level as an endocrinological parameter, to try to 
arrive at an objective criterion in evaluating what 
separates women and men in sports competi-
tions, which could prevent the initiation of com-
plicated, lengthy and damaging sex and gender 
veriﬁ  cation procedures.         
  I N T R O D U C T I O N  
  In 1949, the Dutch track athlete Foekje Dillema 
(1926–2007) came to prominence on the world 
athletic stage. She started to rival Fanny Blankers-
Koen, the world-famous Dutch track athlete who 
won four gold medals during the 1948 Summer 
Olympics in London and was elected Female 
Athlete of the Century by the International 
Association of Athletics Federations (IAAF) in 
1999. In contrast, Dillema’s career was of short 
duration, with a dramatic ending. In 1950, she 
was expelled for life by the Royal Dutch Athletics 
Federation, due to the results of a ‘sex test’, for 
which details or results were never revealed and 
no records are available. Her 1950 national record 
of 24.1 s for the 200 m, which she took from 
Fanny Blankers-Koen, was erased, and only after 
her death 57 years later was she reinstated by the 
Royal Dutch Athletics Federation (  ﬁ  gure 1  ).    1      
  The veriﬁ  cation of the sex of athletes has been 
an issue for many decades. It should be noted that 
reports and reviews on this topic refer to gen-
der veriﬁ  cation, rather than sex veriﬁ  cation.    2      –      4    
However, what counts in competitive sports is 
a person’s sex characteristics. Trying to avoid 
the word sex, given its charged nature, can only 
cause confusion.    5        6    Herein, we will use the term 
sex for the biological and physiological charac-
teristics that deﬁ  ne men and women, as com-
pared to gender and gender identity in reference 
to the socially and individually perceived sexual 
identity of an individual from birth to puberty 
and adulthood.    5        7        8    
  Sex veriﬁ   cation in 1950 was based solely on 
physical examination, predating hormone assays 
or sex chromosome analysis. Following dis-
covery of the Barr body in female cells in 1949, 
it took some 12 years before it was known that 
this body represents an inactivated X chromo-
some    9   ; from the late 1960s its detection was used 
in sex veriﬁ  cation tests in the context of sports 
competitions.    2      –      4    Subsequent tests focused on the 
male-speciﬁ  c region of the Y chromosome, par-
ticularly the male sex determining   SRY   gene.    10    
However, opposition to sex veriﬁ  cation for female 
athletes with laboratory-based genetic testing 
developed in the 1970s and 1980s, because these 
tests did not encompass the complexities of disor-
ders of sex development (DSDs). Since the 2000 
Summer Olympics, questioned sex and gender 
is evaluated on a case-by-case basis by a team of 
specialists in the areas of endocrinology, genetics, 
gynaecology and psychology.    3      –      5    
  To broaden the perspective on sportswomen 
confronted with questioned sex characteristics, 
we have investigated the case of Foekje Dillema, 
with informed consent from her heirs, by means 
of DNA analysis of samples from worn clothing. 
Appreciating the nature of the samples tested, we 
applied DNA methodology and lab quality stan-
dards used in human forensics. Our DNA analysis 
indicates that Foekje Dillema had a 46,XX/46,XY 
mosaic condition with a rare origin, which we 
interpret as leading to hyperandrogenism from her 
puberty. Based on this historical case we discuss 
that, if a sportswoman is confronted with signs 
of a DSD early in her sports career, it is harmful 
and confusing to question such a person’s sex and 
gender. Rather, we suggest that it is necessary to 
try to arrive at an objective criterion in evaluat-
ing what separates women and men in sports 
competitions.   
    RECONSTRUCTION OF A HISTORICAL CASE 
  From the combined genotyping and DNA quanti-
ﬁ  cation results, we conclude that Foekje Dillema 
was a 46,XX/46,XY mosaic, with equal num-
bers of both genetic cell types at least in her skin 
(online supplementary data). In the fetal gonads 
of a 46,XX/46,XY mosaic, the tissue ratio of 
XX:XY cells will push the bipotential gonads to 
become either ovaries or testes, or both. A pre-
ponderance of 46,XX cells in fetal gonads can 
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lead to the development of ovaries, but with some 46,XY 
testis tissue present in one or both of these ovaries. Such an 
ovotestis condition, which can also occur in the form of a 
complete ovary and a complete testis on either side, has been 
referred to with the term true hermaphroditism.    11        12    The most 
common karyotype found in true hermaphroditism is 46,XX, 
followed by 46,XX/46,XY chimerism and mosaicism.    12    We 
would like to emphasise that the term hermaphrodite, as 
well as other terms such as intersex, need to be replaced by 
the DSDs classiﬁ  cation proposed by consensus in 2006,    13    for 
the simple reason that the terms hermaphrodite and inter-
sex cannot, and should not, be applied to human individuals. 
Instead, a true hermaphrodite is correctly referred to as either 
a female or male individual with ovotesticular DSD.    13    When 
ovotestis formation is conﬁ  ned to only one of the gonads, the 
other gonad and the ovarian part of the ovotestis can func-
tion as steroidogenic ovarian tissue.    11        12    The testicular part 
of the fetal ovotestis will produce anti-Müllerian hormone, 
insulin-like factor 3 and testosterone,    14    acting towards regres-
sion of Müllerian ducts, initiation of testis descent and partial 
virilisation by circulating androgens, respectively, but none of 
these effects might reach a level where overt fetal virilisation 
leads to the birth of a boy. Hence, an individual with ovotes-
ticular DSD often is raised as a girl,    12    and also experiences a 
female gender identity (described below). 
  The X:Y ratio in the adult skin, as we obtained from 
Dillema’s clothes, does not provide any information about the 
ratio in her fetal gonads. However, Foekje Dillema was for-
mally registered as a female at birth, and she was raised as a 
girl, according to all accounts, including those available from 
her family. Hence, she is unlikely to have been exposed to a 
markedly elevated level of testosterone during fetal develop-
ment. From all available data, including the present DNA evi-
dence, we deduce that Dillema had an ovotesticular DSD with 
a predominance of ovarian tissue. At the onset of puberty, 
gonadotropic stimulation of the gonads most likely led to 
marked activation of steroidogenesis – the production of both 
 Figure  1        Foekje Dillema (in white shirt on the left) together with 
Fanny Blankers-Koen, on the Olympic Day, 18 June 1950, in the 
Olympic Stadium, Amsterdam, when 60 000 spectators witnessed 
Dillema winning the 200 m in 24.1 s, in a race in which Blankers-
Koen did not participate.   1    Photo: Ben van Meerendonk (collection 
International Institute of Social History, Amsterdam).   
oestradiol and testosterone in Dillema’s case of ovotesticular 
DSD. From photographs, it is evident that from puberty she 
had breast development, but personal accounts also indicate 
that she showed some facial hair growth.    1    Hyperandrogenism 
from puberty may have contributed to Dillema’s athletic 
performance.   
    SEX CHARACTERISTICS, GENDER IDENTITY AND 
TESTOSTERONE 
  To have, or not to have, a Y chromosome is the primary deci-
sive factor in human sexual differentiation, but there are 
exceptions. A prominent example is offered by 46,XY females 
who have the complete form of androgen insensitivity syn-
drome (cAIS), when the testes produce testosterone but the 
body is not able to respond to androgens (testosterone and its 
more powerful metabolite dihydrotestosterone) due to muta-
tion of the X-encoded androgen receptor.    14    Consequently, 
these individuals are born and raised as girls, and have a 
female gender identity.    15        16    Action of testosterone through 
binding to the androgen receptor in the developing fetal brain 
is the predominant factor in programming human male gen-
der identity,    7        17    and the female gender identity of 46,XY cAIS 
women is explained by loss of this androgenic effect. In sports, 
46,XY cAIS women can be expected to have a disadvantage 
compared to 46,XX women with a functional androgen recep-
tor, the latter proﬁ  ting from stimulation of muscle strength by 
a low level of circulating testosterone.    18        19    
  The biological basis for sex segregation in sports is the con-
sequence of long-term endogenous androgen exposure of men 
after puberty.    20     It cannot be excluded that proteins encoded by 
genes in the male-speciﬁ  c region of the Y chromosome (MSY)    21    
might act together with androgens, widening the physiologi-
cal gap between women and men. However, such a role for 
MSY genes will be minor, compared to the predominant role 
of androgen action. In men, the postpubertal testosterone level 
is a proven dose-dependent factor when muscle strength and 
other physiological factors such as the blood haemoglobin level 
come into play.    22    A moderate pubertal and postpubertal excess 
of testosterone in a young woman can give extra muscle devel-
opment and other signs of hyperandrogenism, but it would be 
a rude error to even suggest that this would affect her female 
gender identity. 
  Competitive athletes exploit fortunate combinations of 
natural differences in physical and mental personal charac-
teristics, including individual variation of the endogenous 
testosterone level. The World Anti-Doping Agency states 
that an athlete’s sample will be found positive if the con-
centration of an endogenous androgenic steroid hormone is 
above the range normally found in humans, and is not likely 
consistent with normal endogenous production, unless the 
elevated concentration of the steroid hormone (or metabo-
lites or markers) is attributable to a physiological or patholog-
ical condition.    23     Strictly speaking, a female athlete is free to 
beneﬁ  t from any endogenous source of androgen production. 
Some female athletes may beneﬁ  t, probably to a small extent, 
from increased androgen production originating from a poly-
cystic ovary.    19    This is viewed as acceptable by the IAAF, who 
stated that conditions that may provide some advantages but 
nevertheless are acceptable include congenital adrenal hyper-
plasia, androgen-producing tumours and an ovulatory andro-
gen excess associated with a polycystic ovary.    24     According 
to these regulations, h yperandrogenism caused by ovotes-
ticular DSD would be unacceptable only if sex and gender 
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veriﬁ  cation would provide evidence that the female athlete 
in fact is a man. However, we consider it highly unlikely that 
any individual would aim to participate in sports competi-
tions in conﬂ  ict with his or her gender identity. There is no 
problem in sports at large that warrants an examination, ini-
tiated by a sports federation, of the authenticity of an adult 
individual’s sex and gender. Hence, there is a need to recon-
sider the situation. 
  It might be considered to set an upper limit for the circu-
lating total testosterone level for sportswomen. In cases of 
cAIS, a high testosterone level would be of no signiﬁ  cance. 
In any other case where the total testosterone level is found 
to exceed a set limit, causes and consequences need to be 
resolved before the sportswoman (re-)enters sports competi-
tion. This would be ethically justiﬁ  able, given the fact that it 
would be in the individual’s own interest to prevent symp-
toms of long-term hyperandrogenism. The causes and con-
sequences of a high-testosterone level can be dealt with in 
private, not in public, and, most importantly, without ques-
tioning gender identity. The eligibility of Dillema to compete 
might still be questioned, even today in the current era of 
improved knowledge about DSDs. However, if an increased 
endogenous testosterone level would have been detected, 
possible treatment to lower this level would have cleared the 
way to competition re-entry, leaving no trace of a sex and 
gender discussion. 
  Obviously, a proper deﬁ   nition of an upper limit for the 
endogenous testosterone level will require a detailed discus-
sion about measurement, metabolites, circadian and other 
variations, binding proteins, etc.    25      –      27    Normative ranges have 
not been well established,    28     but available data indicate that a 
circulating total testosterone level of 3–4 nmol/l normally will 
not be exceeded by women of younger age.    18        29    Leaving all anti-
doping controls ﬁ  ghting against the use of exogenous andro-
gens in place,    30     it might be relatively straightforward to arrive 
at a consensus about the maximally allowed endogenous total 
testosterone level. With 8–12 nmol/l total testosterone being 
considered as a lower limit which may require substitution in 
  What is already known on this topic 
        The complex biology of sex development and its disorders 
appears to preclude a swift and objective assessment of the 
eligibility of speciﬁ  c women athletes to compete with other 
women in competitive sports. Prominent cases, historical and 
recent, have suffered much confusion and resulted in lengthy 
procedures, harmful to both the respective athletes and to 
sports and society at large.     
  What this study adds 
        Describing a historical case, this study puts forward the notion 
that societal appreciation of sex and gender issues in highly 
competitive sports requires discussion and understanding of 
relevant biomedical knowledge. However, the authenticity 
of an adult individual’s sex and gender identity should not be 
  questioned. Rather, there is a need for an objective and relevant 
criterion in evaluating what separates women and men in 
sports  competitions.   
men,    27    and with a reference range of 11–35 nmol/l for men,    31    
there is a substantial and signiﬁ  cant gap in the testosterone 
level between women and men. 
  It has been argued that sex is not a binary quantity, with 
the far-reaching implication that sex segregation in competi-
tive sports is an inconsistent and unjust policy.    32     This argu-
ment was substantiated by pointing out that an individual’s 
genetic background may cause a differential sensitivity to 
testosterone. Indeed, a genetic polymorphism such as the 
CAG repeat polymorphism in exon 1 of the gene encoding 
the androgen receptor affects the sensitivity of cells and tis-
sues to androgens.    33     However, this effect is likely far too 
small    34     to provide any female athlete with an advantage 
bringing her on par with male athletes. Such a common 
genetic variation should not be taken into account and does 
not obstruct the prevailing thought that women and men are 
to compete separately, meaning that there is a need for a 
dividing line.    35     Thinking about a dividing line, there is much 
agreement that current principles and procedures need to be 
revisited.    35      –      37    
  The historical case described herein concerns ovotesticular 
DSD, where the amount of steroidogenic testicular tissue will 
determine if the affected person develops as a woman or as 
a man, regarding both gender and sexual characteristics. As 
such, this type of DSD can be viewed as a paradigm, dem-
onstrating that the testosterone level might offer an objec-
tive parameter to separate the sexes, if required. In fact, this 
parameter is already implemented, in the context of sports. 
Athletes (46,XY and androgen sensitive) who have undergone 
male-to-female sex reassignment are welcome to engage in 
sports competitions from 2 years after the sex change, as of 
the Olympic Games 2004 in Athens, according to fortunate 
and emancipative regulations by the International Olympic 
Committee.    38     Similarly, athletes (46,XX and androgen sensi-
tive) who have undergone female-to-male sex reassignment 
can compete, but they will receive exogenous testosterone. 
For female-to-male sex-reassigned individuals receiving tes-
tosterone supplementation, a total testosterone level of around 
30 nmol/l has been reported.    39     Perhaps, one day we may wit-
ness a talented 46,XX sex-reassigned male who is able to suc-
cessfully compete with 46,XY males, thanks also to approved 
testosterone supplementation. Men exposed to stress and 
exhaustion face difﬁ  culty in maintaining their endogenous 
testosterone level,    40      –      42    which might imply an advantage for 
46,XX sex-reassigned males, particularly in endurance sports. 
Similarly, a therapeutic use exemption for long-term testos-
te r o n e  a dmini s tr a ti o n  in  46 ,XY  m e n,  t o  c o m p e ns a te  f o r  a  
secondary loss of gonadal testosterone production, might 
provide an advantage. The above serves to illustrate the point 
that current concepts and regulations regarding the relation-
ship between sex and testosterone in sports offer room for 
consideration. We feel that this should be taken as a starting 
point to discuss the circulating testosterone level as a relevant 
criterion in evaluating what separates women and men in 
sports competitions. 
  The present report is not meant to provide a guideline, 
which would require detailed analysis of total testosterone 
levels in large numbers of female and male athletes in rela-
tion to possible confounding factors, and consensus meetings. 
Rather, we aim to contribute to an open discussion involving 
experts from the ﬁ  elds of biology, medicine, genetics, psychol-
ogy, sports and ethics, to accomplish a procedure which would 
respect the authenticity of an adult individual’s sex and gender 
identity.         
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Note  On 12 April 2011, the International Association of Athletics Federations 
(IAAF) announced the adoption of new rules and regulations governing the 
eligibility of females with hyperandrogenism to participate in women’s competition, 
which will come into force from 1 May 2011 (http://www.iaaf.org/aboutiaaf/news/
newsid=59746.html).
It appears that these new IAAF rules, as announced, are in full agreement 
with the viewpoint expressed in our article, which at the time of the IAAF 
announcement was already in press with the British Journal of Sports Medicine. 
We would like to emphasise that our viewpoint was composed independently from 
IAAF, and that none of the authors has been in contact with the respective IAAF 
expert working group.
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